Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for pegcetacoplan (Empaveli) for C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in adults and adolescents 12 years of age and older.